Distribution of ETV6-ABL Fusion Gene in Hematopoietic Cell Populations of Myeloproliferative Neoplasm / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1242-1246, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-888545
ABSTRACT
OBJECTIVE@#To explore the expression level of ETV6-ABL fusion gene in different cell populations in patients with myeloproliferative neoplasm (MPN) and therapeutic effect of tyrosine kinase inhibitor (TKI).@*METHODS@#A 42-year-old man who presented with fever, marked leukocytosis and chronic myelogenous leukemia (CML) like MPN was reported. ETV6-ABL fusion gene was detected by real-time PCR and confirmed by direct sequencing. ETV6-ABL mRNA expression in each cell population sorted from peripheral blood by flow cytometry was detected by real-time PCR.@*RESULTS@#ETV6-ABL fusion gene was found out in bone marrow cells and confirmed as type A by direct sequencing. ETV6-ABL fusion gene transcript level in polymorphonuclear cells was nearly 3.6-fold relative to that in total cells, which was significantly higher than that in T cell, B cell and monocyte subsets. The complete blood count (CBC) returned to normal level after treatment with imatinib (400 mg) daily for three months. After TKI treatment for 6 months, the ratio of ETV6-ABL/ABL decreased from 174.1% to 1.9%.@*CONCLUSION@#ETV6-ABL fusion gene positive MPN may have a CML clinical presentation and is sensitive to TKI. ETV6-ABL fusion gene is specifically expressed in polymorphonuclear cells.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Genes abl
/
Proteínas de Fusão bcr-abl
/
Transplante de Células-Tronco Hematopoéticas
/
Mesilato de Imatinib
/
Transtornos Mieloproliferativos
Limite:
Adulto
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS